Understanding Canine Plasmacytomas: Solitary vs. Systemic Disease

Plasma cell tumors arise from the abnormal cloning of B-lymphocytes that have differentiated into antibody-secreting plasma cells. In dogs, these are generally categorized into two distinct clinical presentations: solitary extramedullary plasmacytomas (SEPs) and multiple myeloma. SEPs are typically found in the skin, ears, or mucous membranes and are generally benign.

The Spectrum of Plasma Cell Neoplasia

Unlike lymphoma, which often involves widespread lymphadenopathy, plasmacytomas are localized. However, they can mimic other dermal lesions such as a mast cell tumor or squamous cell carcinoma. Distinguishing these requires careful diagnostic pathology.

Clinical Indicators and Diagnostic Warning Signs

Pet owners often first notice a small, firm, or slightly raised red-purple nodule on the skin. While these are usually painless, they can ulcerate if they grow rapidly or become irritated by friction.

When to Seek Emergency Care

If you notice lethargy, increased thirst, or unexplained bruising, this could indicate progression toward systemic involvement. Unlike hemangiosarcoma, which presents as an acute internal rupture, plasmacytoma complications are usually related to high protein levels in the blood, known as hyperviscosity syndrome.

Diagnostic Approaches to Plasma Cell Tumors

Diagnosis begins with a fine-needle aspirate (FNA), which allows a pathologist to identify the classic "fried egg" appearance of plasma cells under a microscope. If the mass is located internally, such as near the gastrointestinal stromal tumor sites, imaging via ultrasound or CT scan is necessary.

Histopathology and Staging

For definitive diagnosis, a biopsy is gold standard. If multiple myeloma is suspected, veterinarians will conduct a serum chemistry panel to check for hyperglobulinemia and evaluate bone marrow samples, which helps rule out other mimics like osteosarcoma or metastatic mammary tumor spread.

Treatment Modalities and Therapeutic Goals

For most cutaneous plasmacytomas, surgical excision is curative. The goal is to obtain clean margins, ensuring no tumor cells remain. If surgery is not an option—such as for tumors in difficult locations—radiation therapy is highly effective.

Managing Systemic Malignancy

Multiple myeloma requires systemic chemotherapy. While not as aggressive as the treatment for transitional cell carcinoma, it does require careful monitoring of kidney function and blood protein levels.